Everest Pharmaceutical

06/06/2026

e-Updates

"Resistance training and diabetes mellitus type 2: An umbrella review of systematic reviews and meta-analyses on glycemic and cardiometabolic outcomes"

•
Resistance training delivers consistent cardiometabolic benefits in T2D—especially glycaemia and blood pressure. Across 43 included systematic reviews/meta-analyses, resistance training vs non-exercise typically reduced HbA1c by ~0.3–0.6 %-points, fasting glucose by ~0.5–1.4 mmol/L, and systolic BP by ~4–7 mmHg, with modest improvements in LDL/total cholesterol and triglycerides, and mixed HDL findings.
•
Consistent improvements in muscle strength, while body weight/BMI effects are small or null (with modest reductions more likely for waist circumference and body fat %). Physical health-related quality of life shows small benefits, whereas overall/mental HRQoL findings are inconsistent.
•
Confidence is “moderate” for the main clinical endpoints, but constrained by overlap, heterogeneity, and review-method limitations. GRADE certainty was moderate for HbA1c, LDL-C, triglycerides, and systolic BP; low–moderate for fasting glucose and diastolic BP; and low for fasting insulin, HDL-C, and mental/overall HRQoL.

Metabolism - Clinical and Experimental. 2026

Read more on our blog:
www.everestpharmaceuticals.com.np

01/06/2026

22/05/2026

e-Updates

"Maternal Diabetes and Risk of Early-Onset Cardiovascular Diseases in Offspring"

The study included 4 274 414 individuals (51.39% male; mean [SD] age, 27.4 [15.0] years at the end of follow-up), of whom 61 336 (1.46%) were exposed to maternal diabetes and 4 213 078 (98.56%) were not exposed. During a median 27.6 years (IQR, 17.2-37.4 years) of follow-up, 7.36% of total participants had a diagnosis of cardiovascular diseases (CVD). Any maternal diabetes was associated with an increased risk of overall CVD in offspring (HR, 1.16; 95% CI, 1.12-1.20); risk of CVD was higher for pregestational diabetes (HR, 1.29; 95% CI, 1.21-1.38) than for gestational diabetes (HR, 1.11; 95% CI, 1.05-1.17). These associations were also found in sibling analyses. Increased risks in offspring prenatally exposed to maternal diabetes were found for some CVD subtypes, including venous thromboembolism (HR, 1.20; 95% CI, 1.07-1.34), cerebrovascular diseases (HR, 1.31; 95% CI, 1.12-1.52), atrial fibrillation (HR, 1.27; 95% CI, 1.05-1.54), and heart failure (HR, 1.65; 95% CI, 1.37-2.00). In mediation analyses, CHD, preterm birth, and LGA directly and/or indirectly mediated 31.87%, 16.06%, and 14.18% of the association between any diabetes and offspring CVD risk, respectively.

This cohort study found that maternal diabetes during pregnancy was associated with increased long-term risks of overall CVD and some CVD subtypes in offspring, particularly following pregestational diabetes. These findings highlight the importance of associations of perinatal and early-life factors and offspring CVD risk later in life, especially in mothers with diabetes.

JAMA Cardiology. 2026
Read more on our blog:
www.everestpharmaceuticals.com.np

15/05/2026

e-Updates

"Safety of Very Low LDL-Cholesterol: Ten Common Concerns, Misconceptions, and Evidence-Based Clarifications"

Highlights
•
Achieving very low LDL-C levels provides proportional ASCVD risk reduction, supporting “lower for longer” strategies in high-risk patients.
•
Across randomized trials and meta-analyses, intensive LDL-C lowering shows no consistent signal of major harm, including at very low achieved levels.
•
Available evidence from blinded trials, meta-analyses, and genetic studies does not indicate a clinically meaningful increase in cognitive impairment or cancer with intensive LDL-C lowering.
•
The main safety considerations are statin-associated dysglycaemia/new-onset diabetes and muscle symptoms; absolute excess risk is modest, concentrated in those with higher baseline glycaemic risk, and outweighed by larger absolute ASCVD event reductions.
•
Clear LDL-C definitions and transparent absolute risk–benefit communication can reduce therapeutic inertia and improve long-term adherence to lipid-lowering therapy.

Atherosclerosis. 2026
Read more on our blog:
www.everestpharmaceuticals.com.np

25/04/2026

20/04/2026

e-Updates

"Biomarkers in heart failure"

Heart failure (HF) is a leading cause of morbidity and mortality worldwide, characterized by a complex pathophysiology and heterogeneous clinical trajectories. Circulating biomarkers have progressively moved from ancillary diagnostic tools to indispensable instruments that inform diagnosis, prognostication, and therapeutic guidance. B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) remain the cornerstones of biomarker-guided management, yet their interpretation is influenced by age, renal function, obesity, and atrial fibrillation. Cardiac troponins, originally validated for myocardial infarction, provide robust prognostic information in both acute and chronic HF by reflecting ongoing myocardial injury, while high-sensitivity C-reactive protein (hsCRP) captures systemic inflammation and its impact on outcomes. The scope of biomarker research has rapidly expanded to novel pathways. Galectin-3 (Gal-3) and soluble suppression of tumorigenicity-2 (sST2) are established mediators of fibrosis and remodeling, offering incremental prognostic value beyond natriuretic peptides. Growth differentiation factor-15 (GDF-15), myeloperoxidase (MPO), and mid-regional pro-adrenomedullin (MR-proADM) integrate systemic stress, congestion, and oxidative injury into risk assessment. More recently, non-coding RNAs—including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs)—have emerged as minimally invasive, pathophysiologically grounded biomarkers with diagnostic, prognostic, and even therapeutic implications. Looking ahead, multimarker strategies that combine complementary pathways provide a multidimensional perspective on HF progression and therapeutic response. Advances in high-throughput omics platforms and artificial intelligence (AI) promise to refine biomarker integration into precision medicine, enabling individualized risk stratification and therapy optimization. Altogether, biomarkers now represent essential pillars of modern HF care and hold the potential to transform management from population-based to personalized strategies.

(Advances in Clinical Chemistry, Elsevier. 2026)

Read more on our blog:
www.everestpharmaceuticals.com.np

14/04/2026

Everest Pharmaceuticals wishes you all a very Happy New Year, 2083.

always dedicated to create a positive impact on quality of life of patients.